ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lorlatinib

Also written as “Lorlatinib”, “PF-06463922” and “Lorlatinib 50 mg”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms · Carcinoma · Renal Insufficiency, led by 4 companies.

Drug pageLorlatinib: every studyAll 45 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 22, 202020 company-led studies, 5 open or runningNext primary completion: Nov 30, 2028

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only173 open or runningphase 4since Apr 22, 2020Oct 16, 2013Nov 30, 2028NCT06487078
CStone Pharmaceuticalsits history only11 open or runningphase 2since Mar 17, 2022Mar 17, 2022none ahead
Hoffmann-La Roche11 open or runningphase 1since May 14, 2026May 14, 2026Aug 31, 2030phase 1 · NCT07617337
Strata Oncologyits history only10 open or runningphase 2since Oct 1, 2021Oct 1, 2021none ahead

Also a collaborator on its studies: Merck and Gilead Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2015Named lorlatinibINNProposed as its International Nonproprietary Name in WHO's List 114 · before, PF-06463922
  2. May 14, 2026First study: phase 1 study in ALK Positive Non-small Cell Lung CancerFirst studyNCT07617337 · 102 planned · United States, Japan

Ahead

  1. Aug 31, 2030Primary completion: phase 1 study in ALK Positive Non-small Cell Lung CancerNCT07617337

TargetBeta

ALK →EML4 →read by rule
“An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), ”NCIt, by rule
“ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
CrizotinibrulePfizerphase 431

Studies

The one study Hoffmann-La Roche leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07617337ALK Positive Non-small Cell Lung Cancer · United States, Japan1RecruitingAug 31, 2030102

How it is read

Names in the registry

  • “Lorlatinib”, 10 entries
  • “PF-06463922”, 8 entries
  • “lorlatinib”, 6 entries
  • “Lorlatinib 50 mg”, 1 entry
  • “Lorlatinib 75 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.